Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas

Shalaka S. Hampras, Raphael P Viscidi, Kathy J. Helzlsouer, Ji Hyun Lee, William J. Fulp, Anna R. Giuliano, Elizabeth A Platz, Dana E. Rollison

Research output: Contribution to journalArticle

Abstract

John Cunningham virus (JCV) is a common polyomavirus classified as a possible carcinogen by the International Agency for Research on Cancer. JCV may play a role in colorectal carcinogenesis, although we previously reported no association between JCV capsid antibodies and colorectal cancer. No studies have examined the role of seroreactivity to JCV T-antigen (T-Ag) oncoprotein in colorectal cancer. A case-control study nested within a community-based prospective cohort (CLUE II) was conducted. In 1989, 25,080 residents of Washington County, Maryland, were enrolled inCLUEII, completing baseline questionnaires and providing blood samples. At follow-up, 257 incident colorectal cancer cases were identified by linkage to population-based cancer registries through 2006 and matched to controls on age, sex, race, and date of blood draw. One hundred and twenty-three colorectal adenoma cases were identified through self-report during follow-up and matched to controls on age, sex, race, date of blood draw, and colorectal cancer screening. Baseline serum samples were tested for seroreactivity to JCV T-Ag. Associations between JCV T-Ag seroreactivity and colorectal cancer/adenomas were evaluated using conditional logistic regression models. Overall, seroreactivity to JCV T-Ag was not statistically significantly associated with the risk of either colorectal cancer [OR, 1.34; 95% confidence interval (CI), 0.89-2.01] or adenoma (OR, 1.30; 95% CI, 0.70-2.42), while a borderline association with colorectal cancer was observed among women (OR, 1.82; 95% CI, 1.00-3.31). Our past evaluation of JCV capsid seropositivity, combined with current findings, does not support a notable etiologic role for JCV infection in colorectal cancer.

Original languageEnglish (US)
Pages (from-to)2591-2596
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

JC Virus
Viral Tumor Antigens
Adenoma
Colorectal Neoplasms
Prospective Studies
Capsid
Confidence Intervals
Logistic Models
International Agencies
Polyomavirus
Oncogene Proteins
Virus Diseases
Early Detection of Cancer
Carcinogens
Self Report
Registries
Case-Control Studies
Neoplasms
Carcinogenesis

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Medicine(all)

Cite this

Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas. / Hampras, Shalaka S.; Viscidi, Raphael P; Helzlsouer, Kathy J.; Lee, Ji Hyun; Fulp, William J.; Giuliano, Anna R.; Platz, Elizabeth A; Rollison, Dana E.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 23, No. 11, 01.11.2014, p. 2591-2596.

Research output: Contribution to journalArticle

Hampras, Shalaka S. ; Viscidi, Raphael P ; Helzlsouer, Kathy J. ; Lee, Ji Hyun ; Fulp, William J. ; Giuliano, Anna R. ; Platz, Elizabeth A ; Rollison, Dana E. / Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas. In: Cancer Epidemiology Biomarkers and Prevention. 2014 ; Vol. 23, No. 11. pp. 2591-2596.
@article{ea1a861757924af18dd00b00c525bb48,
title = "Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas",
abstract = "John Cunningham virus (JCV) is a common polyomavirus classified as a possible carcinogen by the International Agency for Research on Cancer. JCV may play a role in colorectal carcinogenesis, although we previously reported no association between JCV capsid antibodies and colorectal cancer. No studies have examined the role of seroreactivity to JCV T-antigen (T-Ag) oncoprotein in colorectal cancer. A case-control study nested within a community-based prospective cohort (CLUE II) was conducted. In 1989, 25,080 residents of Washington County, Maryland, were enrolled inCLUEII, completing baseline questionnaires and providing blood samples. At follow-up, 257 incident colorectal cancer cases were identified by linkage to population-based cancer registries through 2006 and matched to controls on age, sex, race, and date of blood draw. One hundred and twenty-three colorectal adenoma cases were identified through self-report during follow-up and matched to controls on age, sex, race, date of blood draw, and colorectal cancer screening. Baseline serum samples were tested for seroreactivity to JCV T-Ag. Associations between JCV T-Ag seroreactivity and colorectal cancer/adenomas were evaluated using conditional logistic regression models. Overall, seroreactivity to JCV T-Ag was not statistically significantly associated with the risk of either colorectal cancer [OR, 1.34; 95{\%} confidence interval (CI), 0.89-2.01] or adenoma (OR, 1.30; 95{\%} CI, 0.70-2.42), while a borderline association with colorectal cancer was observed among women (OR, 1.82; 95{\%} CI, 1.00-3.31). Our past evaluation of JCV capsid seropositivity, combined with current findings, does not support a notable etiologic role for JCV infection in colorectal cancer.",
author = "Hampras, {Shalaka S.} and Viscidi, {Raphael P} and Helzlsouer, {Kathy J.} and Lee, {Ji Hyun} and Fulp, {William J.} and Giuliano, {Anna R.} and Platz, {Elizabeth A} and Rollison, {Dana E.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1158/1055-9965.EPI-14-0370",
language = "English (US)",
volume = "23",
pages = "2591--2596",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas

AU - Hampras, Shalaka S.

AU - Viscidi, Raphael P

AU - Helzlsouer, Kathy J.

AU - Lee, Ji Hyun

AU - Fulp, William J.

AU - Giuliano, Anna R.

AU - Platz, Elizabeth A

AU - Rollison, Dana E.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - John Cunningham virus (JCV) is a common polyomavirus classified as a possible carcinogen by the International Agency for Research on Cancer. JCV may play a role in colorectal carcinogenesis, although we previously reported no association between JCV capsid antibodies and colorectal cancer. No studies have examined the role of seroreactivity to JCV T-antigen (T-Ag) oncoprotein in colorectal cancer. A case-control study nested within a community-based prospective cohort (CLUE II) was conducted. In 1989, 25,080 residents of Washington County, Maryland, were enrolled inCLUEII, completing baseline questionnaires and providing blood samples. At follow-up, 257 incident colorectal cancer cases were identified by linkage to population-based cancer registries through 2006 and matched to controls on age, sex, race, and date of blood draw. One hundred and twenty-three colorectal adenoma cases were identified through self-report during follow-up and matched to controls on age, sex, race, date of blood draw, and colorectal cancer screening. Baseline serum samples were tested for seroreactivity to JCV T-Ag. Associations between JCV T-Ag seroreactivity and colorectal cancer/adenomas were evaluated using conditional logistic regression models. Overall, seroreactivity to JCV T-Ag was not statistically significantly associated with the risk of either colorectal cancer [OR, 1.34; 95% confidence interval (CI), 0.89-2.01] or adenoma (OR, 1.30; 95% CI, 0.70-2.42), while a borderline association with colorectal cancer was observed among women (OR, 1.82; 95% CI, 1.00-3.31). Our past evaluation of JCV capsid seropositivity, combined with current findings, does not support a notable etiologic role for JCV infection in colorectal cancer.

AB - John Cunningham virus (JCV) is a common polyomavirus classified as a possible carcinogen by the International Agency for Research on Cancer. JCV may play a role in colorectal carcinogenesis, although we previously reported no association between JCV capsid antibodies and colorectal cancer. No studies have examined the role of seroreactivity to JCV T-antigen (T-Ag) oncoprotein in colorectal cancer. A case-control study nested within a community-based prospective cohort (CLUE II) was conducted. In 1989, 25,080 residents of Washington County, Maryland, were enrolled inCLUEII, completing baseline questionnaires and providing blood samples. At follow-up, 257 incident colorectal cancer cases were identified by linkage to population-based cancer registries through 2006 and matched to controls on age, sex, race, and date of blood draw. One hundred and twenty-three colorectal adenoma cases were identified through self-report during follow-up and matched to controls on age, sex, race, date of blood draw, and colorectal cancer screening. Baseline serum samples were tested for seroreactivity to JCV T-Ag. Associations between JCV T-Ag seroreactivity and colorectal cancer/adenomas were evaluated using conditional logistic regression models. Overall, seroreactivity to JCV T-Ag was not statistically significantly associated with the risk of either colorectal cancer [OR, 1.34; 95% confidence interval (CI), 0.89-2.01] or adenoma (OR, 1.30; 95% CI, 0.70-2.42), while a borderline association with colorectal cancer was observed among women (OR, 1.82; 95% CI, 1.00-3.31). Our past evaluation of JCV capsid seropositivity, combined with current findings, does not support a notable etiologic role for JCV infection in colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=84920138785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920138785&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-14-0370

DO - 10.1158/1055-9965.EPI-14-0370

M3 - Article

C2 - 25128403

AN - SCOPUS:84920138785

VL - 23

SP - 2591

EP - 2596

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11

ER -